Key Points
- CEO Ethan Phd Shen purchased 3,100 YD Bio shares at an average price of $3.93, investing $12,183. Following the transaction, he owned 11,245,631 shares, a 0.03% increase in his stake.
- YD Bio shares opened at $3.90, compared with a 52-week range of $1.70 to $25.00. The stock’s 50-day moving average was $2.98, while its 200-day moving average was $4.53.
- The biotechnology company reported quarterly EPS of $0.05 and revenue of $0.42 million; meanwhile, Geode Capital Management increased its YD Bio stake by 10% to 58,363 shares.
YD Bio Limited (NASDAQ:YDES - Get Free Report) CEO Ethan Phd Shen bought 3,100 shares of the business's stock in a transaction that occurred on Wednesday, September 9th. The shares were acquired at an average price of $3.93 per share, for a total transaction of $12,183.00. Following the completion of the transaction, the chief executive officer owned 11,245,631 shares in the company, valued at $44,195,329.83. This trade represents a 0.03% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink.
YD Bio Price Performance
Shares of YD Bio stock opened at $3.90 on Friday. YD Bio Limited has a twelve month low of $1.70 and a twelve month high of $25.00. The company's fifty day moving average is $2.98 and its 200 day moving average is $4.53.
YD Bio (NASDAQ:YDES - Get Free Report) last released its quarterly earnings results on Tuesday, September 1st. The biotechnology company reported $0.05 EPS for the quarter. The company had revenue of $0.42 million during the quarter.
Institutional Trading of YD Bio
A hedge fund recently raised its stake in YD Bio stock. Geode Capital Management LLC raised its stake in YD Bio Limited (NASDAQ:YDES - Free Report) by 10.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 58,363 shares of the biotechnology company's stock after purchasing an additional 5,292 shares during the period. Geode Capital Management LLC owned 0.08% of YD Bio worth $711,000 as of its most recent SEC filing.
About YD Bio
(
Get Free Report)
YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
